Overview

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC
Phase:
Phase 3
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Carboplatin
Gemcitabine